From the prodromal stage of multiple sclerosis to disease prevention

Marrie, Ruth Ann; Allegretta, Mark; Barcellos, Lisa F.; Bebo, Bruce; Calabresi, Peter A.; Correale, Jorge; Davis, Benjamin; De Jager, Philip L.; Gasperi, Christiane; Greenbaum, Carla; Helme, Anne; Hemmer, Bernhard; Kanellis, Pamela; Kostich, Walter; Landsman, Douglas; Lebrun-Frenay, Christine; Makhani, Naila; Munger, Kassandra L.; Okuda, Darin T.; Ontaneda, Daniel; Postuma, Ronald B.; Quandt, Jacqueline A.; Roman, Sharon; Saidha, Shiv; Sormani, Maria Pia; Strum, Jon; Valentine, Pamela; Walton, Clare; Zackowski, Kathleen M.; Zhao, Yinshan und Tremlett, Helen (2022): From the prodromal stage of multiple sclerosis to disease prevention. In: Nature Reviews Neurology, Bd. 18, Nr. 9: S. 559-572

Abstract

In this Roadmap, Marrie and colleagues set out the steps needed to improve our understanding of the multiple sclerosis (MS) prodrome and develop standardized criteria for identifying individuals with prodromal MS, thereby facilitating trials of interventions that could slow progression to classical MS. A prodrome is an early set of signs or symptoms that indicate the onset of a disease before more typical symptoms develop. Prodromal stages are well recognized in some neurological and immune-mediated diseases such as Parkinson disease, schizophrenia, type 1 diabetes mellitus and rheumatoid arthritis. Emerging evidence indicates that a prodromal stage exists in multiple sclerosis (MS), raising the possibility of intervention at this stage to delay or prevent the development of classical MS. However, much remains unclear about the prodromal stage of MS and considerable research is needed to fully characterize the prodrome and develop standardized criteria to reliably identify individuals with prodromal MS who are at high risk of progressing to a diagnosis of MS. In this Roadmap, we draw on work in other diseases to propose a disease framework for MS that incorporates the prodromal stage, and set out key steps and considerations needed in future research to fully characterize the MS prodrome, identify early disease markers and develop standardized criteria that will enable reliable identification of individuals with prodromal MS, thereby facilitating trials of interventions to slow or stop progression beyond the prodrome.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin > Munich Cluster for Systems Neurology (SyNergy)
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• Sprache: Englisch
• DFG: Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - 390857198